Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

Background: We investigated the association between skin rash and plasma creatine kinase (CK) levels in oncology phase I trials. Methods: We analysed data from 295 patients treated at our institution within 25 phase I trials which included CK measurements in the protocol. Trials involved drugs targe...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2012-11, Vol.107 (11), p.1797-1800
Main Authors: Moreno Garcia, V, Thavasu, P, Blanco Codesido, M, Molife, L R, Vitfell Pedersen, J, Puglisi, M, Basu, B, Shah, K, Iqbal, J, de Bono, J S, Kaye, S B, Banerji, U
Format: Article
Language:English
Subjects:
631/45/607/1172
692/1807/1812
692/308/2779/109/1940
692/699/67/1059
Antineoplastic Agents - adverse effects
Antitumor agents
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Brain research
Cancer Research
Clinical Study
Clinical trials
Clinical Trials, Phase I as Topic
Creatine Kinase - blood
Dermatology
Drug Resistance
Epidemiology
Exanthema - blood
Exanthema - chemically induced
Humans
Keratinocytes - enzymology
Medical research
Medical sciences
Molecular Medicine
Oncology
Plasma
Retrospective Studies
Skin involvement in other diseases. Miscellaneous. General aspects
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: We investigated the association between skin rash and plasma creatine kinase (CK) levels in oncology phase I trials. Methods: We analysed data from 295 patients treated at our institution within 25 phase I trials which included CK measurements in the protocol. Trials involved drugs targeting EGFR/HER2, m-TOR, VEGFR, SRC/ABL, aurora kinase, BRAF/MEK, PARP, CDK, A5B1 integrin, as well as oncolytic viruses and vascular disrupting agents. Results: Creatine kinase measurements were available for 278 patients. The highest levels of plasma CK during the trial were seen among patients with Grade (G) 2/3 rash (median 249 U l −1 ) compared with G1 (median 81 U l −1 ) and no rash (median 55 U l −1 ) ( P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2012.482